Lipid Metabolism Practice Questions

Q: At which positions does pancreatic lipase hydrolyze the ester linkages of triacylglycerides?

1 and 3. **Correct: 1 and 3** - Pancreatic lipase specifically targets the **ester bonds at the sn-1 and sn-3 positions** (primary alcohol positions) on the glycerol backbone of triacylglycerides. - This positional specificity results in the formation of **2-monoacylglycerol (2-MAG)** and **two free fatty acids**. - This is the characteristic action of pancreatic triacylglycerol lipase during fat digestion in the intestinal lumen. *Incorrect: 1 and 2* - Hydrolysis at positions 1 and 2 would produce a 3-monoacylglycerol and free fatty acids, which is not the physiological product of pancreatic lipase. - The enzyme's positional specificity favors the outer sn-1 and sn-3 positions, not the middle sn-2 position. *Incorrect: 2 and 3* - Hydrolysis at positions 2 and 3 would yield a 1-monoacylglycerol and free fatty acids, which does not reflect pancreatic lipase activity. - The enzyme specifically spares the sn-2 position due to its structural specificity. *Incorrect: Only 3* - If only position 3 were hydrolyzed, the product would be a 1,2-diacylglycerol and one free fatty acid. - This represents incomplete hydrolysis; pancreatic lipase typically hydrolyzes **both outer positions (sn-1 and sn-3)** due to its regiospecificity.

Q: What is the primary product of fatty acid oxidation (β-oxidation)?

Acetyl CoA. ***Acetyl CoA*** - Beta-oxidation of fatty acids involves a series of reactions that cleave two-carbon units from the fatty acyl chain, forming **acetyl CoA**. - **Acetyl CoA** is the direct product of each cycle of β-oxidation and then enters the **citric acid cycle** to generate ATP or serves as a precursor for other anabolic pathways. *Malonyl CoA* - **Malonyl CoA** is a key intermediate in **fatty acid synthesis**, not degradation. - It's formed from acetyl CoA by acetyl-CoA carboxylase and acts as a substrate for **fatty acid synthase**, and also as a physiological inhibitor of carnitine palmitoyltransferase I (CPT-I), thereby regulating β-oxidation. *Ketone bodies* - **Ketone bodies** (**acetoacetate** and **β-hydroxybutyrate**) are produced from acetyl CoA in the liver during conditions of low glucose availability or prolonged fasting. - They serve as an alternative fuel source for tissues like the brain and muscles, but are secondary products derived from the condensation of acetyl CoA molecules, not the primary direct product of fatty acid breakdown itself. *Cholesterol* - **Cholesterol** is a steroid lipid synthesized from **acetyl CoA** through a complex multi-step pathway (via HMG-CoA reductase pathway). - It is an important structural component of cell membranes and a precursor for steroid hormones and bile acids, but not a direct product of fatty acid catabolism.

Q: Which lipoprotein level is affected by LCAT deficiency?

HDL. ***HDL*** - **LCAT (Lecithin-cholesterol acyltransferase)** is crucial for the maturation of **HDL (High-Density Lipoprotein)**. - LCAT esterifies cholesterol in HDL, enabling it to accept more free cholesterol from peripheral tissues, thus a deficiency leads to dysfunctional and decreased mature HDL. *LDL* - **LDL (Low-Density Lipoprotein)** formation primarily involves the breakdown of VLDL and IDL by lipoprotein lipase and hepatic lipase, not directly LCAT activity. - While an LCAT deficiency can indirectly affect lipid metabolism, its direct impact on LDL levels is less pronounced compared to HDL. *VLDL* - **VLDL (Very-Low-Density Lipoprotein)** is synthesized in the liver and transports triglycerides, with its metabolism being largely independent of LCAT. - LCAT's primary role is in **reverse cholesterol transport** and HDL maturation, not VLDL synthesis or catabolism. *Chylomicron* - **Chylomicrons** are formed in the intestines and transport dietary triglycerides and cholesterol, with their metabolism involving lipoprotein lipase. - LCAT does not directly affect the synthesis or breakdown of chylomicrons, which are primarily concerned with exogenous lipid transport.

Q: Which hormone inhibits hormone-sensitive lipase?

Insulin. ***Insulin*** - **Insulin** is a key anabolic hormone that promotes energy storage and inhibits catabolic processes, including the breakdown of triglycerides. - It directly inhibits **hormone-sensitive lipase (HSL)** activity, thus reducing the release of free fatty acids from adipose tissue. *Thyroid hormone* - **Thyroid hormones** (T3 and T4) generally promote catabolism and increase metabolic rate, including the mobilization of lipids. - They tend to **stimulate rather than inhibit** hormone-sensitive lipase expression and activity. *GH* - **Growth hormone (GH)** has lipolytic effects, meaning it promotes the breakdown of fats to provide energy. - GH typically **stimulates HSL activity** and increases the release of free fatty acids from adipocytes. *ACTH* - **Adrenocorticotropic hormone (ACTH)** primarily stimulates the adrenal cortex to produce cortisol. - **Cortisol** can have lipolytic effects in certain contexts and does not directly inhibit HSL; instead, catecholamines act as direct stimulators of HSL.

Q: What is the metabolic abnormality associated with Zellweger syndrome?

Accumulation of very long-chain fatty acids. ***Accumulation of very long-chain fatty acids*** - **Zellweger syndrome** is a peroxisomal biogenesis disorder, meaning that peroxisomes, which are responsible for the **beta-oxidation** of very long-chain fatty acids (VLCFAs), are absent or dysfunctional. - The inability to break down **VLCFAs** leads to their accumulation in various tissues, causing significant neurological and systemic dysfunction. *Accumulation of long-chain fatty acids* - While peroxisomes can contribute to the metabolism of some **long-chain fatty acids (LCFAs)**, their primary role in this context is with **VLCFAs**. - **Mitochondria** are the main organelles responsible for the beta-oxidation of most LCFAs. *Accumulation of short-chain fatty acids* - **Short-chain fatty acids (SCFAs)** are primarily produced by gut bacteria and are metabolized in the mitochondria and other cellular compartments. - Their accumulation is not characteristic of **Zellweger syndrome**. *Accumulation of medium-chain fatty acids* - **Medium-chain fatty acids (MCFAs)** are primarily metabolized in the **mitochondria** and do not typically accumulate in Zellweger syndrome. - Disorders affecting MCFA metabolism usually point to different enzyme deficiencies, such as **MCAD deficiency.**

Q: Which of the following statements is true regarding medium chain fatty acids?

All of the options are true. ***All of the options are true*** - This option is correct because medium-chain fatty acids (MCFAs) possess unique metabolic properties that differentiate them from long-chain fatty acids (LCFAs), making all listed statements accurate. - Their shorter chain length allows for distinct digestion, absorption, and metabolic fates, which are beneficial in various clinical contexts. *Do not require pancreatic lipase for digestion* - MCFAs have **shorter carbon chains** (typically 6-12 carbons) and are more hydrophilic than LCFAs. - This property allows them to be digested by **lingual and gastric lipases** to a greater extent, reducing the reliance on pancreatic lipase. *Absorb directly into portal circulation* - Unlike LCFAs, which are re-esterified into triglycerides, packaged into **chylomicrons**, and absorbed into the lymphatic system, MCFAs are absorbed directly into the **portal vein**. - This bypasses the lymphatic system and directly transports them to the liver, making them a rapid energy source. *Are less likely to be deposited in adipose tissue compared to long-chain fatty acids* - MCFAs are **rapidly oxidized** in the liver for energy via beta-oxidation and are less likely to be stored as triglycerides in adipose tissue. - They are also not efficiently utilized for the synthesis of complex lipids or stored fat due to their unique metabolic pathway and preference for oxidation.

Q: Lipogenesis is stimulated by?

Insulin. ***Insulin*** - **Insulin** is a key anabolic hormone that promotes the synthesis and storage of fat (lipogenesis) by increasing the uptake of glucose into adipose tissue and stimulating enzymes involved in fatty acid synthesis. - It enhances the conversion of excess carbohydrates into **triglycerides** for storage. *Glucagon* - **Glucagon** is a catabolic hormone that primarily promotes the breakdown of glycogen (glycogenolysis) and fat (lipolysis) to release glucose and fatty acids into the bloodstream, especially during fasting. - It generally **inhibits** lipogenesis and stimulates **gluconeogenesis**. *Epinephrine* - **Epinephrine** (adrenaline) is a stress hormone that promotes the breakdown of fat (lipolysis) to provide energy during acute stress or exercise. - It would **inhibit** lipogenesis, as its primary role is to mobilize energy stores. *Corticosteroids* - While **corticosteroids** can influence fat metabolism, their effect on lipogenesis is complex and often indirect. High levels can lead to fat redistribution (e.g., central obesity) rather than direct stimulation of overall lipogenesis. - Corticosteroids generally promote **lipolysis** in the extremities and can contribute to insulin resistance, which would hinder lipogenesis in some tissues.

Q: What is the rate-controlling enzyme of fatty acid synthesis?

Acetyl-CoA carboxylase. ***Acetyl-CoA carboxylase*** - **Acetyl-CoA carboxylase (ACC)** catalyzes the committed step in fatty acid synthesis, converting **acetyl-CoA** to **malonyl-CoA**. - This enzyme is subject to both allosteric regulation (e.g., activation by **citrate** and inhibition by **long-chain fatty acyl-CoA**) and hormonal regulation (e.g., phosphorylation by glucagon and dephosphorylation by insulin). *Thioesterase* - **Thioesterase** is the enzyme responsible for releasing the completed fatty acid chain from the **fatty acid synthase complex**. - While essential for the termination of synthesis, it does not regulate the initiation or overall rate of the pathway. *Transacetylase* - **Transacetylase** (specifically, acetyl-CoA-ACP transacetylase and malonyl-CoA-ACP transacetylase) is involved in transferring acetyl and malonyl groups to the **acyl carrier protein (ACP)** within the fatty acid synthesis complex. - This is an intermediary step, but not the primary **rate-controlling** or committed step. *Ketoacyl synthase* - **Ketoacyl synthase (or β-ketoacyl-ACP synthase)** is responsible for condensing the growing acyl chain with malonyl-ACP, leading to the formation of a **β-ketoacyl-ACP**. - This is a crucial chain elongation step within the fatty acid synthase complex, but not the enzyme that controls the overall commitment to fatty acid synthesis.

Q: Which of the following is required for fatty acid synthesis ?

NADPH. ***NADPH*** - **NADPH** is crucial for fatty acid synthesis, providing the **reducing power** needed for the successive reduction steps. - The enzymes involved, such as **fatty acid synthase**, utilize **NADPH** for the conversion of keto groups to hydroxyl groups and then to saturated methylene groups. *NADH* - **NADH** plays a primary role in **oxidative phosphorylation** and the electron transport chain to generate ATP. - It is generally produced during **catabolic reactions** and is not primarily used as a reducing agent in anabolic processes like fatty acid synthesis. *FADH* - **FADH2** (reduced form of FAD, not FADH) is a coenzyme involved in redox reactions, particularly in the **Krebs cycle** and beta-oxidation of fatty acids. - Like NADH, it is mostly involved in **catabolic processes** that generate energy, rather than anabolic processes requiring reducing equivalents for synthesis. *None of the options* - This option is incorrect because **NADPH** is indeed required for fatty acid synthesis, serving as the essential reducing agent. - The other coenzymes mentioned (NADH, FADH) have different metabolic roles, primarily in energy production rather than biosynthesis.

Q: Enzyme deficient in Type I Hyperlipidemia?

Lipoprotein lipase. ***Lipoprotein lipase*** - **Type I hyperlipidemia**, also known as **familial hyperchylomicronemia**, is characterized by a deficiency in **lipoprotein lipase (LPL)**. - LPL is crucial for hydrolyzing triglycerides in **chylomicrons** and **VLDLs** into fatty acids and glycerol, allowing their uptake by tissues. *HMG CoA reductase* - This enzyme is involved in the **rate-limiting step of cholesterol synthesis** in the liver. - While it plays a role in lipid metabolism, its deficiency is not characteristic of **Type I hyperlipidemia**. *Peroxidase* - **Peroxidase** is an enzyme involved in various oxidative reactions, including the breakdown of **hydrogen peroxide**. - It is not directly involved in the metabolism of **chylomicrons** or **triglycerides**, and its deficiency is unrelated to hyperlipidemia. *Cholesterol acyl transferase* - This enzyme, often referring to **lecithin-cholesterol acyltransferase (LCAT)** or **acyl-CoA:cholesterol acyltransferase (ACAT)**, is involved in **cholesterol esterification**. - While important for cholesterol transport and storage, its deficiency is not the primary cause of **Type I hyperlipidemia**, which is marked by severe **chylomicronemia**.

Question 1

At which positions does pancreatic lipase hydrolyze the ester linkages of triacylglycerides?

Accepted Answer

1 and 3

Answer

1 and 2

Answer

2 and 3

Answer

Only 3

Question 2

What is the primary product of fatty acid oxidation (β-oxidation)?

Accepted Answer

Acetyl CoA

Answer

Malonyl CoA

Answer

Ketone bodies

Answer

Cholesterol

Question 3

Which lipoprotein level is affected by LCAT deficiency?

Accepted Answer

HDL

Answer

LDL

Answer

VLDL

Answer

Chylomicron

Question 4

Which hormone inhibits hormone-sensitive lipase?

Accepted Answer

Insulin

Answer

GH

Answer

ACTH

Answer

Thyroid hormone

Question 5

What is the metabolic abnormality associated with Zellweger syndrome?

Accepted Answer

Accumulation of very long-chain fatty acids

Answer

Accumulation of long-chain fatty acids

Answer

Accumulation of short-chain fatty acids

Answer

Accumulation of medium-chain fatty acids

Question 6

Which of the following statements is true regarding medium chain fatty acids?

Accepted Answer

All of the options are true

Answer

Do not require pancreatic lipase for digestion

Answer

Absorb directly into portal circulation

Answer

Are less likely to be deposited in adipose tissue compared to long-chain fatty acids

Question 7

Lipogenesis is stimulated by?

Accepted Answer

Insulin

Answer

Glucagon

Answer

Epinephrine

Answer

Corticosteroids

Question 8

What is the rate-controlling enzyme of fatty acid synthesis?

Accepted Answer

Acetyl-CoA carboxylase

Answer

Thioesterase

Answer

Transacetylase

Answer

Ketoacyl synthase

Question 9

Which of the following is required for fatty acid synthesis ?

Accepted Answer

NADPH

Answer

NADH

Answer

FADH₂

Answer

None of the options

Question 10

Enzyme deficient in Type I Hyperlipidemia?

Accepted Answer

Lipoprotein lipase

Answer

HMG CoA reductase

Answer

Peroxidase

Answer

Cholesterol acyl transferase

Lipid Metabolism — MCQs

Lipid Metabolism — MCQs

On this page

Practice by Chapter

Want unlimited practice?